Evidence map›Paper›PMID 33553125›Full record

ReviewFrontiers in bioengineering and biotechnology2020

Heat Shock Proteins 90 kDa: Immunomodulators and Adjuvants in Vaccine Design Against Infectious Diseases.

Mariana G Corigliano, Valeria A Sander, Edwin F Sánchez López, Víctor A Ramos Duarte, Luisa F Mendoza Morales, Sergio O Angel, Marina Clemente

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Article
  5. TargetingVaccines · 2024
    Review
  6. Article
  7. Organismal Roles of Hsp90.Biomolecules · 2023
    Review
  8. Heat Shock Protein 90's Mechanistic Role in Contact Hypersensitivity.Journal of immunology (Baltimore, Md. : 1950) · 2022
    Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Mariana G CoriglianoUnidad Biotecnológica 6-UB6, Laboratorio de Molecular Farming y Vacunas, INTECH, UNSAM-CONICET, Chascomús, Argentina.
Valeria A SanderUnidad Biotecnológica 6-UB6, Laboratorio de Molecular Farming y Vacunas, INTECH, UNSAM-CONICET, Chascomús, Argentina.
Edwin F Sánchez LópezUnidad Biotecnológica 6-UB6, Laboratorio de Molecular Farming y Vacunas, INTECH, UNSAM-CONICET, Chascomús, Argentina.
Víctor A Ramos DuarteUnidad Biotecnológica 6-UB6, Laboratorio de Molecular Farming y Vacunas, INTECH, UNSAM-CONICET, Chascomús, Argentina.
Luisa F Mendoza MoralesUnidad Biotecnológica 6-UB6, Laboratorio de Molecular Farming y Vacunas, INTECH, UNSAM-CONICET, Chascomús, Argentina.
Sergio O AngelUnidad Biotecnológica 2-UB2, Laboratorio de Parasitología Molecular, INTECH, UNSAM-CONICET, Chascomús, Argentina.
Marina ClementeUnidad Biotecnológica 6-UB6, Laboratorio de Molecular Farming y Vacunas, INTECH, UNSAM-CONICET, Chascomús, Argentina.
National University of General San Martín · ARConsejo Nacional de Investigaciones Científicas y Técnicas · AR

Funding

Novel components of Homologous Recombination Repair in the parasite Toxoplasma gondiiR01AI129807 · NIAID · INSTITUTE/RESEARCH/BIOTECHNOLOGY FDN · PI ANGEL, SERGIO OSCAR · 2017 to 2021
$650k
NIAID NIH HHS R01 AI129807
6 · The paper itself

Abstract

Heat shock proteins 90 kDa (Hsp90s) were originally identified as stress-responsive proteins and described to participate in several homeostatic processes. Additionally, extracellular Hsp90s have the ability to bind to surface receptors and activate cellular functions related to immune response (cytokine secretion, cell maturation, and antigen presentation), making them very attractive to be studied as immunomodulators. In this context, Hsp90s are proposed as new adjuvants in the design of novel vaccine formulations that require the induction of a cell-mediated immune response to prevent infectious diseases. In this review, we summarized the adjuvant properties of Hsp90s when they are either alone, complexed, or fused to a peptide to add light to the knowledge of Hsp90s as carriers and adjuvants in the design of vaccines against infectious diseases. Besides, we also discuss the mechanisms by which Hsp90s activate and modulate professional antigen-presenting cells.

Indexed as

carrierchaperonescross-presentationgp96GRP94Hsp90MHC class Ire-presentation

Identifiers

PMID33553125
PMCPMC7855457
OpenAlexW3124748059

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.